Since SARS-CoV-2 can induce the production of IL-1β, different IL-1β, and IL-1β receptors antagonising therapeutics have been tested in hospitalised COVID-19 patients with ARDS in the attempt to reduce the hyperinflammatory CRS. The gene discussed is IL1B; the disease is acute respiratory distress syndrome.